Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) National Institute for Health and Care Excellence, (b) NHS England, (c) the Medicines and Healthcare products Regulatory Agency, (d) the National Institute for Health and Care Research and (e) the Medical Research Council on (i) expediting and (ii) improving access to (A) novel treatments, (B) therapeutics and (C) technologies for brain cancer patients.

The Department recognises that there are currently limited treatment options available for people who have been diagnosed with brain tumours, and the significant impact that rarer forms of cancer can have on patients, carers, and their families. That is why the Department is committed to working closely with partners and patient groups to shape the long-term vision for cancer.

The Department has regular discussions with system partners on a number of topics, including access to novel treatments, therapeutics, and technologies for brain cancer patients. The National Institute for Health and Care Excellence evaluates the clinical and cost effectiveness of all new licensed medicines, including for the treatment of brain cancer, and aims to issue guidance on whether they should be routinely funded by the National Health Service in England as close as possible to licensing.

The Department has engaged widely with stakeholders as part of the development of the National Cancer Plan, which will include further details on how the Government will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology.

Furthermore, a new national Brain Tumour Research Consortium was established in December 2024, funded by the National Institute for Health and Care Research, to bring together researchers from a range of different disciplines and institutions with the aim of driving scientific advancements in how to prevent, detect, manage, and treat cancers in adults and children. The work being undertaken by the consortium aims to ensure that patients have access to the latest treatments and technology and to clinical trials.

The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.

The Medicines and Healthcare products Regulatory Agency is engaging with industry and patient stakeholder groups to see how the agency can encourage research and product licencing in this area. It remains focused on enabling safe access to innovative treatment as rapidly as possible.